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Abstract
An EU-wide cooperation on HTA has been proposed recently by the European Commission, focusing on relative efective-
ness assessment (REA) for pharmaceuticals and medical devices. This cooperation is operationalised through a proposal 
for a regulation. While a good step in the right direction, this HTA cooperation framework needs to be more explicit and 
pragmatic about clinical value deinition, what constitutes quality of evidence, how real-world evidence is handled, whether 
the same assessment requirements will apply for medical devices as they do for pharmaceuticals, and how to safeguard con-
sistency in REA interpretation. If demand-rather than supply-driven, this initiative can deliver wider beneits: Europe can 
improve its power in global drug design and development, while Member States will have at their disposal more resources 
to assess performance of interventions in their healthcare systems.
Background
On January 31st, 2018, the European Commission released 
a proposal for a new regulation on health technology 
assessment (HTA) cooperation. This aims, among others, 
to streamline disparate national HTA processes and gener-
ate a single, joint clinical assessment, with a focus on joint 
relative efectiveness assessment (REA) of pharmaceuticals 
and certain types of medical devices, the promotion of early 
dialogues and the identiication of emerging technologies 
and other opportunities for voluntary cooperation [1]. Right-
fully, the scope of the draft regulation is limited to “assess-
ment” of technologies (i.e. the scientiic consideration), 
while “appraisal” (i.e. the decision rule) remains a national 
competence. The proposal has drawn on extensive impact 
assessment of diferent policy options, which, among others, 
found duplication in Member States’ HTA processes and 
argued in favour of a faster and more uniform assessment 
and greater equity in the availability of innovative health 
technologies [2]; recently, the proposal received an opinion 
from the European Parliament [3].
Although the draft regulation aims to provide a common 
foundational framework for HTA at EU level, it falls short of 
addressing a number of much needed changes in the assess-
ment of medical technologies and adapting to the reality 
of post-clinical and post-launch data generation. Scientiic 
challenges in novel drug discovery and development [4] and 
the ever-increasing use of accelerated forms of marketing 
authorisation by the European Medicines Agency (EMA) 
and other regulatory agencies provide the backdrop to the 
need for change by both HTAs and manufacturers.
Speciically, the HTA draft regulation needs to provide 
a clearer steer on what constitutes clinical value; clarify 
aspects relating to the quality of evidence; clarify what is the 
use of real-world evidence (RWE) in joint assessments and 
beyond; outline how should medical devices be assessed; 
and ensure consistency in REA interpretation.
Clinical value deinition
The credibility of a collaborative assessment at European 
level and its subsequent uptake by national competent 
authorities depend on the robustness of the process and the 
criteria that underpin it. In that context, it would be desir-
able to see a clearer deinition and a more common under-
standing of what ‘clinical value’ is, infused with a degree of 
pragmatism. Beyond a technology’s clinical efectiveness 
and safety, dimensions such as burden of disease, severity 
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and the level of unmet need for new treatments could be 
acknowledged or even accounted for. The irst four of the 
nine domains of the European Network of Health Technol-
ogy Assessment (EUnetHTA) HTA Core Model for Rapid 
Relative Efectiveness [5] could serve as a starting point 
in this discussion. It also needs to be recognised that in a 
number of clinical areas the traditional model of double-
blind, randomised clinical trials (RCTs) may be impossible 
or impractical to implement. In some Member States, the 
mechanisms used are often too inlexible to acknowledge 
that. Clearer guidance is needed on additional evidence 
requirements that may follow the initial evidence genera-
tion. Development of common methodological guidance by 
Member State HTA bodies (as envisaged under the proposed 
regulation), could help address this; such guidance could 
substitute the current polyphony that exists in individual 
Member States about the acceptability or not of individual 
pieces of evidence. This transcends the issue of HTA and 
creates an opportunity for Europe to establish much needed 
infrastructure as well as a validated value framework by 
accounting for what is feasible or acceptable and what is not.
Quality of evidence
A major area underpinned by signiicant challenges and 
where clear guidance is needed relates to what constitutes 
appropriate or acceptable quality of evidence and its assess-
ment. A number of challenges are involved here. First, there 
is a divergence between the ‘political’ and the ‘patient-cen-
tric’ drive to faster approvals, increasingly through regula-
tory early access schemes or clinical evidence with imma-
ture data [6–8], but from an HTA perspective there is an 
increasing demand for evidence, more comprehensive data 
and more relevant comparators. While manufacturers may 
need to shift certain components of evidence generation to 
an earlier stage, this may not be possible across the board. 
Second, often conventional trial designs are not ethically 
acceptable, particularly in late stage disease when there is 
no standard of care, or when there is no active comparator 
available. Third, there is signiicant variability in the accept-
ance of comparators in diferent settings. By recognising 
this reality, EU HTA can also infuse more pragmatism in 
the evidentiary requirements of clinical assessment. This 
could mean, for example, a readiness to accept data where 
cohorts from RWE can compare survival in the real popu-
lation versus the trial results, based on recently developed 
methods [9, 10]. Equally, there needs to be an acceptance 
of individual or mixed-treatment comparisons or indirect 
treatment comparisons in two- as well as single-arm trials 
(SATs) and a need for a general framework on when SATs 
are acceptable. There also needs to be recognition in evi-
dence assessment of the heterogeneity of treatments in terms 
of the diferences between the treatments themselves and the 
speed with which science is moving, for example through 
shorter time horizons compared with current data extrapola-
tions over long time horizons, as well as clear signals about 
additional evidence generation if HTA submissions rely on 
immature data.
If, as its proponents suggest, the proposed regulation 
becomes mandatory, then  there needs to be some  clar-
ity on how promising products with less mature or earlier 
phase data or data from non-randomised studies, will be 
treated from an assessment perspective. This is because 
the regulatory view, through EMA’s accelerated or condi-
tional approval pathways, difers from the HTA view, which 
is much more conservative, considering uncertainties of 
evidence. If there is no clarity, then such products run the 
risk of a generalised ‘rejection’ on account of insuicient 
evidence. This, in turn, may conlict with the EC’s objective 
of improving the availability of innovative health technolo-
gies. There is a signiicant value arising from EUnetHTA 
in terms of facilitating a sustainable HTA collaboration in 
Europe and, more speciically, on methodology advances 
[11]. Equally, the proposed regulation has made provisions 
for joint scientiic consultations, which, in turn, can pro-
vide clarity on evidence requirements. Still, the HTA col-
laboration needs to pro-actively relect on the challenges 
posed by data generation and adopt a forward-looking 
perspective. The value of the cooperation would increase 
exponentially if early scientiic advice could take place 
amongst European HTA agencies and if they all sign up 
to one, harmonised evidence generation base. But, unfor-
tunately, this is unlikely to be the case; early advice initia-
tives identify where there may be agreements and then they 
identify where there are divergencies or disagreements, as 
for example relating to the appropriateness of comparators, 
among other things. Whilst early dialogue may provide some 
transparency, it is unlikely to expedite access to patients, 
unless Member States also cooperate to streamline their evi-
dentiary requirements, possibly through such an expedited 
pathway for promising technologies with ‘immature’ data. 
The above represent areas that need to be addressed through 
collaborative work.
Real‑world evidence
The use of RWE is key to the proposed EU regulation. In 
some diseases, the value resonates in having long cohort data 
over many years, whereas in others, which could be driven by 
speciic genetic subtypes, companion diagnostics and testing 
become very important. Obtaining these data from existing 
databases is usually not possible, necessitating the wider avail-
ability and use of registry data. A key challenge from an HTA 
perspective remains the variable acceptance of RWE. Despite 
An EU-wide approach to HTA: An irrelevant development or an opportunity not to be missed? 
1 3
improvements in infrastructure, issues remain with access to 
data in several Member States, including privacy issues, the 
lack of incentives for data sharing, availability and use, and 
the ongoing debate about RWE distrust. It is, therefore, fun-
damental to have a discussion on what needs RWE is going to 
fulil. For example, while studying uncertainty in long-term 
efectiveness remains key, it is also important to study how 
the efectiveness of a new therapy can re-shape clinical prac-
tice. Having this ex ante clarity will also drive methodological 
and empirical developments in RWE generation further. If we 
accept the argument that bringing RWE into decision mak-
ing will improve the quality of decisions and that expertise is 
needed on both sides of the data continuum, then these issues 
need to be addressed urgently.
Pharmaceuticals vs. medical devices
HTA for medical devices poses signiicant challenges, par-
ticularly for small companies, in terms of fulilling evidence 
requirements. Medical devices have a shorter life cycle than 
pharmaceuticals and the market is much more competitive 
as patents are easier to circumvent for medical devices, 
consequently, while long RCTs may be desirable from an 
evidence standpoint, they may not always be appropriate or 
feasible for medical devices. Unlike pharmaceuticals, medi-
cal device companies do not have data exclusivity, which 
means that companies who do not conduct clinical studies on 
their own device can often claim equivalence [12] to another 
device that is already on the market. Transitioning to a joint 
mandatory REA from a number of fragmented national and 
regional HTA processes, could represent a signiicant barrier 
to entry for medical device suppliers, the majority of which 
are small and medium-sized enterprises (SMEs).
Additionally, the number of medical devices far exceeds 
that of pharmaceuticals and performing HTA on all medi-
cal devices would be extremely resource intensive for all 
stakeholders involved even in the subset of devices envis-
aged by the proposed regulation (class IIb and III and sub-
ject to a scrutiny mechanism). Both assessments and re-
assessments can be challenging in the medical device sector 
given the frequency of product modiications, the level of 
competition and the timing of competitor entry, which is 
much faster than in pharmaceuticals. Additional competi-
tors will enter the market and have an impact on the price 
of an existing product, possibly placing irst entrants at a 
disadvantage, creating an obvious barrier to entry for the 
irst-in-class, which is absent for all followers in that class. 
Evidence requirements in HTA often tend to be strictest for 
irst movers in a therapeutic area and this is likely to afect 
medical devices more given the market dynamics in this sec-
tor. Finally, there needs to be a common understanding about 
appropriate comparators for a treatment, as it is well known 
that countries vary substantially in deining these. The same 
holds for a number of therapy areas as well, such as cancer 
therapy, as current standard of care often difers between 
countries. In sum, EU HTA needs to be more circumspect 
about the need for REAs in medical devices and perhaps 
deine the need, the associated evidence requirements and 
a methodological framework guiding these more tightly, 
beyond joint scientiic consultations providing advice on 
study designs.
Consistency in REA interpretation
A inal issue relates to the consistency of REA interpretation 
and the ex ante deinition of the rules of the game. There 
may be competing interests and diferent remits among the 
80 plus EUnetHTA partner organisations from 30 countries, 
even among partners from the same country, which may lead 
to diferences in assessments. Additionally, how factors 
such as indirect comparisons and RWE are able to provide 
a predictable interpretation of that evidence is important to 
clarify. EU-wide REAs would be beneicial so long as the 
reproducibility of any report and a predictable pathway to 
their interpretation by national competent authorities can 
be guaranteed. If this is not the case, then the unavoidable 
consequence will be further duplication of the overall HTA 
efort. To that end, independent assessments from a tertiary 
group of experts and based on common principles could 
minimise this.
Overall beneits from collaborative EU HTA
The extent to which a mandatory EU-wide HTA process will 
reduce duplication and achieve eiciency gains depends on 
whether such an assessment results in (a) clarity and trans-
parency in evidence requirements across therapeutic areas, 
enhanced by systematic early dialogue; (b) consistency of 
methods and their acceptability, recognizing the peculiarities 
and challenges of modern drug development; (c) clarity on 
the timing of performing REAs and, therefore, predictability 
of outcomes; and (d) a greater dialogue between the regula-
tory side (EMA) and HTAs around alignment of evidence 
requirements. This by no means implies centralisation of 
HTA processes; rather, common methods, joint scientiic 
consultations and joint clinical assessments are expected to 
be synergistic.
There is a perception that because centralisation has 
been achieved for marketing authorisation, the same can be 
done for HTA. The two are completely diferent: centrali-
sation of regulation results in a decision applicable to all, 
whereas HTA is not a decision, but a collection, synthesis 
and analysis of diferent information pieces that are subject 
to interpretation prior to arriving at a recommendation. The 
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challenge in making this latter process mandatory is a chal-
lenge about making EU HTA demand-rather than supply-
driven. If it is demand-driven and Member States use this 
information to shape national priorities, then there is value 
in generating it. But if it is supply-driven and the objective 
is to be churning out reports to inform the rest of Europe, 
then there is a danger of more duplication, unless there is 
buy-in from decision makers on the value of those reports. 
Assuming a demand-driven EU HTA, there needs to be con-
sensus on a template for REAs; the need for such a template 
is already recognised by the proposed regulation.
The EU HTA cooperation is unlikely to result in substan-
tial savings, as HTA bodies and national competent authori-
ties will still want to understand local epidemiology and 
need, conduct budget impact analysis and negotiate pric-
ing. But it can result in beneits for Member States and for 
Europe. Member States can free up and re-allocate resources 
to measure performance of interventions in the wider health 
care system (e.g. hospital interventions, primary care); this 
is urgently needed to balance the over-emphasis on drug-
related HTA. From a broader perspective, this initiative 
would enable Europe to improve its negotiating power in 
global drug design and development if views can be aligned 
on evidence requirements. But at the moment they cannot 
and so the FDA and the USA still dictate to a large extent 
what clinical studies measure and what endpoints are used.
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